However, the use of cytotoxic chemotherapy in ACC is based on studies with exceedingly small sample sizes, and their administration is often complicated by toxicity, so they are thus not preferred when VEGFR inhibition is feasible. The gene discussed is KDR; the disease is adrenal cortex carcinoma.